Table 3 Concomitant T2D and CVD/CKD medications at baseline (Prescribed Patient Set)
T2D medication (%) | Endocrinologist N = 1652 | Diabetologist N = 2301 | Cardiologist N = 102 | All HCP specialties N = 4055 |
|---|---|---|---|---|
Metformin | 81.7 | 78.0 | 79.4 | 79.5 |
Sulfonylurea | 37.9 | 22.3 | 16.7 | 28.5 |
Acarbose | 0.2 | 2.1 | 2.9 | 1.4 |
Pioglitazone | 0.2 | 4.0 | 0 | 2.3 |
Insulin | 20.7 | 28.6 | 16.7 | 25.1 |
Others | 3.6 | 4.0 | 6.9 | 3.9 |
CVD/CKD medication (%) | ||||
Antihypertensives (ACEi/ARB) | 76.0 | 66.8 | 85.3 | 71.0 |
Statins | 59.5 | 57.7 | 80.4 | 59.0 |
Low dose aspirin | 33.6 | 27.0 | 62.7 | 30.6 |
β-blockers | 35.1 | 40.1 | 71.6 | 38.8 |
Diuretics | 28.5 | 31.8 | 43.1 | 30.8 |
Others | 9.7 | 19.8 | 28.4 | 15.9 |